Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

sclc317074_S77.txt

— · cohortMD1

de3f8f2b-757c-5b1e-ac6c-19e37d3a97b4

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortMD1
subtype
cohortMD1

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V1+0.530
  • MYC_TARGETS_V2+0.520
  • E2F_TARGETS+0.380
  • G2M_CHECKPOINT+0.290
  • UNFOLDED_PROTEIN_RESPONSE+0.290
  • OXIDATIVE_PHOSPHORYLATION+0.280
  • MTORC1_SIGNALING+0.270
  • PROTEIN_SECRETION+0.240
  • DNA_REPAIR+0.200
  • NOTCH_SIGNALING+0.170

Top 10 suppressed

  • INTERFERON_GAMMA_RESPONSE-0.380
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
  • COMPLEMENT-0.310
  • HEDGEHOG_SIGNALING-0.310
  • ANGIOGENESIS-0.300
  • ALLOGRAFT_REJECTION-0.290
  • INFLAMMATORY_RESPONSE-0.290
  • IL6_JAK_STAT3_SIGNALING-0.270
  • INTERFERON_ALPHA_RESPONSE-0.240
  • KRAS_SIGNALING_UP-0.230

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-33-A4WN-01A-11R-A262-07
lung-landscapes@6
—cohortSQ20.888
2TCGA-77-8143-01A-11R-2247-07
lung-landscapes@6
—cohortSQ10.886
31764b9ab-4f37-47c5-8225-40c574433f40
colon-landscapes@1
——0.885
4MNG449
mng-umap@100
——0.879
5SRR6013542
lung-landscapes@6
—cohortSQ10.878
6SRR26320071
bladder-landscape@3
——0.877
7SRR1313140
breast-umap@18
—E0.873
8MNG1063
mng-umap@100
——0.873
9cabd9320-506a-4695-a18a-7c8602633f90
colon-landscapes@1
——0.873
10e235012b-4b29-478a-abad-6a70cd949cfa
colon-landscapes@1
——0.869

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V10.530Inavolisib— uncovered
MYC_TARGETS_V20.520Idelalisib— uncovered
E2F_TARGETS0.380Inavolisib— uncovered
G2M_CHECKPOINT0.290Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.290Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.280Remibrutinib— uncovered
MTORC1_SIGNALING0.270Inavolisib— uncovered
PROTEIN_SECRETION0.240Remibrutinib— uncovered
DNA_REPAIR0.200Idelalisib— uncovered
NOTCH_SIGNALING0.170Inavolisib— uncovered
GLYCOLYSIS0.160Inavolisib— uncovered
FATTY_ACID_METABOLISM0.140Inavolisib— uncovered
PEROXISOME0.140Idelalisib— uncovered
ANDROGEN_RESPONSE0.130Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.110Remibrutinib— uncovered
PI3K_AKT_MTOR_SIGNALING0.110Inavolisib— uncovered
ADIPOGENESIS0.070Inavolisib— uncovered
BILE_ACID_METABOLISM0.070Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.070Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.060Idelalisib— uncovered